29 articles about Bioretec
Bioretec's ActivaPin™ bioresorbable implant provides good alternative treatment of pediatric elbow injuries
A recently published clinical study confirms the benefits of using fully bioresorbable ActivaPin™ implant together with bioabsorbable suture, for the tension band wire treatment of pediatric medial epicondyle humeral fractures.
Bioretec Ltd's Half Year Report 2022 (unaudited): Strong sales growth and RemeOs™ registrations on-going
In January 2022, Bioretec entered into a supply agreement with Meotec GmbH in Germany for magnesium alloy raw materials for bioresorbable RemeOsTM products.
Bioresorbable Activa IM-Nail™ shows convincing results in Post-Market Clinical Follow-up study for the treatment of children's forearm fractures
Bioretec Ltd ( HELSINKI : BRETEC) Forearm fractures are a common injury in children and adolescents.
Bioretec enters into a distribution agreement with AMI Medical Technologies for bioresorbable Activa products in Israel
Bioretec Ltd has entered into a distribution agreement with AMI Medical Technologies Ltd, a leading distributor of medical devices in Israel.
Resolutions of Bioretec Ltd´s Annual General Meeting and the organizing meeting of the Board of Directors
The Annual General Meeting of shareholders of Bioretec Ltd was held, 13 April 2022 at 12:00 EEST in Tampere.
Bioretec Ltd has published its 2021 Annual Report, Financial Statements and Report by the Board of Directors.
Bioretec enters into a supply agreement with Meotec for magnesium alloy raw materials for bioresorbable RemeOs products
Bioretec Ltd, a globally operating Finnish medical device company and a pioneer in bioresorbable orthopedic implants, has entered into a raw material supply agreement with Meotec GmbH, a German manufacturer of implantable materials.
Bioretec Ltd, a pioneer in bioresorbable orthopedic implants, has submitted an application for the CE mark for the first product in its new RemeOs™ product family, the RemeOs™ trauma screw.